Online weight-loss platform Join Luma uses magazine price ranking to sell tirzepatide bundle

HappyScale Wellness Corp., which operates as Join Luma, is making price the centrepiece of its pitch for compounded tirzepatide. On 11 November 2026 the online weight-management company said it came out cheapest among seven providers in a comparison run by Venture Magazine and published on 6 November.

The company's lead offer is a six-month, self-pay plan aimed at people who already take GLP-1 medicines. It is priced at $149 a month, but customers pay the whole $894 at the outset rather than in instalments. The announcement came from the company itself, and CompePharma has not seen the Venture Magazine piece, so the ranking cannot be independently verified.

Nothing is known about how the comparison was built, who the other six providers were, or what they charged. That makes it hard to judge how large Join Luma's price advantage is, or whether the offers compared like for like.

The release carries its own caveats. It says the compounded product has not gone through FDA approval, has not been assessed by the agency for safety, effectiveness or quality, and that a low price should not be read as showing it matches an authorised medicine. By way of general context, compounded drugs are made by pharmacies outside the regulator's product-approval system, so they are not evaluated in the way approved therapies are.